Emtricitabine and Tenofovir Tablets and Lasmiditan
Determining the interaction of Emtricitabine and Tenofovir Tablets and Lasmiditan and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown. MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary. References "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Professional:GENERALLY AVOID: Coadministration with lasmiditan may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp and BCRP by lasmiditan. The clinical relevance is unknown.
MANAGEMENT: Concomitant use of lasmiditan with drugs that are P-gp and/or BCRP substrates should be avoided when possible. If coadministration is required, patients should be carefully monitored for increased adverse reactions of these drugs and dosing adjusted as necessary.
- "Product Information. Reyvow (lasmiditan)." Lilly, Eli and Company, Indianapolis, IN.
Generic Name: emtricitabine / tenofovir
Brand name: AccessPak for HIV PEP Basic, Descovy, Truvada
Synonyms: Emtricitabine and tenofovir, Emtricitabine and Tenofovir Disoproxil Fumarate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Emtricitabine and Tenofovir Tablets-Latanoprost
- Emtricitabine and Tenofovir Tablets-Latanoprost and netarsudil ophthalmic
- Emtricitabine and Tenofovir Tablets-Latanoprost and Timolol
- Emtricitabine and Tenofovir Tablets-Latanoprost Eye Drops (Emulsion)
- Emtricitabine and Tenofovir Tablets-Latanoprost Eye Drops (Solution)
- Emtricitabine and Tenofovir Tablets-Latanoprost ophthalmic
- Lasmiditan-Emtricitabine Capsules
- Lasmiditan-Emtricitabine Solution
- Lasmiditan-Emtricitabine, lopinavir, ritonavir, and tenofovir
- Lasmiditan-Emtricitabine, nelfinavir, and tenofovir
- Lasmiditan-Emtricitabine, rilpivirine, and tenofovir
- Lasmiditan-Emtricitabine, Rilpivirine, and Tenofovir Alafenamide